Therefore, these two events, induction of the ZEB1-EPB41L5 axis and TP53 mutations, can be complementary to each other in generating and activating the ARF6-based mesenchymal pathway, and may hence cooperatively promotes the mesenchymal malignancy of breast cancer cells. The gene discussed is TP53; the disease is breast carcinoma.